Janus kinase inhibitors for the treatment of myeloproliferative neoplasms

Bibliography

• Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005;7(4):387-97
   PubMed Web of Science ®Google Scholar
• Manshouri T, Estrov Z, Quintás-Cardama A, et al. Bone marrow stroma–secreted cytokines protect JAK2V617F-mutated cells from the effects of a JAK2 inhibitor. Cancer Res 2011;71(11):3831-40
   PubMedGoogle Scholar
• Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009;113(13):2895-901
   PubMed Web of Science ®Google Scholar
• Emanuel RM, Dueck AC, Geyer HL, et al. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol 2012;30(33):4098-103
   PubMed Web of Science ®Google Scholar
• Tefferi A, Siragusa S, Hussein K, et al. Transfusion-dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosis – prognostic relevance is independent of IPSS or karyotype. Am J Hematol 2010;85(1):14-17
   PubMed Web of Science ®Google Scholar
• Hussein K, Pardanani AD, Van Dyke DL, et al. International Prognostic Scoring System–independent cytogenetic risk categorization in primary myelofibrosis. Blood 2010;115(3):496-9
   PubMedGoogle Scholar
• Patnaik MM, Caramazza D, Gangat N, et al. Age and platelet count are IPSS-independent prognostic factors in young patients with primary myelofibrosis and complement IPSS in predicting very long or very short survival. Eur J Haematol 2010;84(2):105-8
   PubMed Web of Science ®Google Scholar
• Gangat N, Caramazza D, Vaidya R, et al. DIPSS plus: a refined dynamic international prognostic scoring system for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 2011;29(4):392-7
   PubMed Web of Science ®Google Scholar
• Mesa RA, Steensma DP, Pardanani A, et al. A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Blood 2003;101(7):2534-41
   PubMed Web of Science ®Google Scholar
• Gisslinger H, Harutyunyan AS, Nivarthi H, et al. Frequent mutations in the calreticulin gene CALR in myeloproliferative neoplasms. Blood 2013;122(21):LBA-1
   Google Scholar
• Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 2013;369(25):2379-90
   PubMed Web of Science ®Google Scholar
• Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 2013;369(25):2391-405
   PubMed Web of Science ®Google Scholar
• Massie C, Baxter EJ, Nice FL, et al. The genomic landscape of myeloproliferative neoplasms: somatic calr mutations in the majority of JAK2-wildtype patients. Blood 2013;122(21):LBA-2
   Google Scholar
• Zhang S-J, Rampal R, Manshouri T, et al. Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome. Blood 2012;119(19):4480-5
   PubMed Web of Science ®Google Scholar
• Vannucchi AM, Lasho TL, Guglielmelli P, et al. Mutations and prognosis in primary myelofibrosis. Leukemia 2013;27(9):1861-9
   PubMed Web of Science ®Google Scholar
• Klampfl T, Harutyunyan A, Berg T, et al. Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression. Blood 2011;118(1):167-76
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A, Vaddi K, Liu P, et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 2010;115(15):3109-17
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 2010;363(12):1117-27
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Kantarjian HM, Estrov Z, et al. Comparison of outcomes of advanced myelofibrosis patients treated with ruxolitinib (INCB018424) to those of a historical control group: survival advantage of ruxolitinib therapy. ASH Annual Meeting Abstracts 2011;118(21):793
   Google Scholar
• Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012;366(9):799-807
   PubMed Web of Science ®Google Scholar
• Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 2012;366(9):787-98
   PubMed Web of Science ®Google Scholar
• Komrokji RS, Sun W, Sandor VA, Verstovsek S. Optimizing dose titration of ruxolitinib: the COMFORT-I experience. Blood 2013;122(21):4062
   Google Scholar
• Cleeland CS, Dantzer R, Sloan J, et al. Cytokine profile changes in 309 myelofibrosis patients: comparison of JAK1/JAK2 inhibitor therapy vs. placebo – correlative analysis from the comfort-I trial. Blood 2013;122(21):4074
   Google Scholar
• Harrison CN, Barosi G, Vannucchi AM, et al. The relationship between cytokine levels and symptoms in patients (Pts) with myelofibrosis (MF) from COMFORT-II, a phase 3 study of ruxolitinib (RUX) vs best available therapy (BAT). Blood 2013;122(21):4070
   Google Scholar
• Cervantes F, Vannucchi AM, Kiladjian JJ, et al. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood 2013;122(25):4047-53
   PubMed Web of Science ®Google Scholar
• McMullin MF, Harrison CN, Niederwieser D, et al. The use of erythropoietic-stimulating agents (ESAs) with ruxolitinib in patients with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), and post-essential thrombocythemia myelofibrosis (PET-MF). ASH Annual Meeting Abstracts 2012;120(21):2838
   Google Scholar
• Verstovsek S, Kiladjian J-J, Mesa RA, et al. Effect of ruxolitinib on the incidence of splenectomy in patients with myelofibrosis: a retrospective analysis of data from ruxolitinib clinical trials. ASH Annual Meeting Abstracts 2012;120(21):2847
   Google Scholar
• Verstovsek S, Gotlib J, Levy RS, et al. Long-term outcomes of ruxolitinib therapy in patients with myelofibrosis: 3-year update from COMFORT-I. Blood 2013;122(21):396
   Google Scholar
• Hagop K, Kiladjian J-J, Gotlib J, et al. A pooled overall survival analysis of the COMFORT studies: 2 randomized phase 3 trials of ruxolitinib for the treatment of myelofibrosis. Blood 2013;122(21):2820
   Web of Science ®Google Scholar
• Thiele J, Bueso-Ramos CE, Sun W, et al. Effects of five-years of ruxolitinib therapy on bone marrow morphology in patients with myelofibrosis and comparison with best available therapy. Blood 2013;122(21):4055
   Google Scholar
• Kvasnicka H-M, Thiele J, Bueso-Ramos CE, et al. Exploratory analysis of the effect of ruxolitinib on bone marrow morphology in patients with myelofibrosis. ASCO Meeting Abstracts 2013;31(15 Suppl):7030
   Google Scholar
• Talpaz M, Paquette R, Afrin L, et al. Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts. J Hematol Oncol 2013;6(1):81
   PubMed Web of Science ®Google Scholar
• Pardanani A, Laborde RR, Lasho TL, et al. Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis. Leukemia 2013;27(6):1322-7
   PubMed Web of Science ®Google Scholar
• Shao L, Deng W, Niforos D, et al. Dose-response analyses of momelotinib (CYT387), a JAK1 and JAK2 inhibitor, from a phase I/II study (CCL09101) in treatment of myelofibrosis. Blood 2013;122(21):1590
   Google Scholar
• Verstovsek S, Passamonti F, Rambaldi A, et al. A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. Cancer 2014;120(4):513-20
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Kiladjian J, Waltzman RJ, et al. RESPONSE: a randomized, open label, phase III study of INC424 in polycythemia vera (PV) patients resistant to or intolerant of hydroxyurea (HU). ASCO Meeting Abstracts 2011;29(15 Suppl):TPS203
   Google Scholar
• Kiladjian J-J, Griesshammer M, Masszi T, et al. Baseline characteristics and symptom burden in RESPONSE: a randomized, open-label, phase 3 study of ruxolitinib in polycythemia vera patients resistant to or intolerant of hydroxyurea. Blood 2013;122(21):4071
   Google Scholar
• Pardanani A, Gotlib J, Jamieson C, et al. SAR302503: interim safety, efficacy and long-term impact on JAK2 V617F allele burden in a phase I/II study in patients with myelofibrosis. ASH Annual Meeting Abstracts 2011;118(21):3838
   Google Scholar
• Pardanani A, Gotlib JR, Jamieson C, et al. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol 2011;29(7):789-96
   PubMed Web of Science ®Google Scholar
• Wernig G, Kharas MG, Okabe R, et al. Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell 2008;13(4):311-20
   PubMed Web of Science ®Google Scholar
• Tefferi A, Jamieson CH, Gabrail NY, et al. Long-term follow up of a randomized phase II study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis (MF). Blood 2013;122(21):4047
   PubMedGoogle Scholar
• Hasserjian RP, Gotlib J, Cortes JE, et al. Effect of treatment with the JAK2-selective inhibitor fedratinib (SAR302503) on bone marrow histology in patients with myeloproliferative neoplasms with myelofibrosis. Blood 2013;122(21):2823
   PubMedGoogle Scholar
• Mesa R. Symptom burden and health related quality of life (HRQoL) in patients with myelofibrosis (MF) treated with Fedratinib (SAR302503) in a phase III study (JAKARTA). Blood 2013;122:Abstract 4061
   Google Scholar
• Harrison CN, Cortes JE, Cervantes F, et al. Results of a randomized, double-blind, placebo-controlled phase III study (JAKARTA) of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis (MF). Blood 2013;122(21):393
   Web of Science ®Google Scholar
• Schaap NP, Zweegman S, Jourdan E, et al. Efficacy and safety of fedratinib (SAR302503/TG101348) in patients with intermediate- or high-risk myelofibrosis (MF), post-polycythemia vera (PV) MF, or post-essential thrombocythemia (ET) MF previously treated with ruxolitinib: interim results from a phase II study (JAKARTA-2). Blood 2013;122(21):661
   Google Scholar
• Komrokji RS, Wadleigh M, Seymour JF, et al. Results of a phase 2 study of pacritinib (SB1518), a novel oral JAK2 inhibitor, in patients with primary, post-polycythemia vera, and post-essential thrombocythemia myelofibrosis. ASH Annual Meeting Abstracts 2011;118(21):282
   Google Scholar
• Dean JP, Cernohous P, Komrokji RS, et al. Pacritinib, a dual JAK2/FLT3 inhibitor: an integrated efficacy and safety analysis of phase II trial data in patients with primary and secondary myelofibrosis (MF) and platelet counts ≤100,000/µl. Blood 2013;122(21):395
   Web of Science ®Google Scholar
• Wang L, Li H, Wada R, Dean JP. Exposure-response analysis for pacritinib (SB1518), a novel oral JAK2/FLT3 inhibitor, in patients with myelofibrosis. Blood 2013;122(21):4080
   Google Scholar
• Pardanani A, Gotlib J, Gupta V, et al. An expanded multicenter phase I/II study of CYT387, a JAK-1/2 inhibitor for the treatment of myelofibrosis. ASH Annual Meeting Abstracts 2011;118(21):3849
   Google Scholar
• Pardanani AD, Caramazza D, George G, et al. Safety and efficacy of CYT387, a JAK-1/2 inhibitor, for the treatment of myelofibrosis. ASCO Meeting Abstracts 2011;29(15 Suppl):6514
   Google Scholar
• Gotlib J, Gupta V, Roberts AW, et al. Update on the long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis. Blood Supplement 2013;122(21):108
   Google Scholar
• Verstovsek S, Mesa RA, Rhoades SK, et al. Phase I study of the JAK2 V617F inhibitor, LY2784544, in patients with myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET). ASH Annual Meeting Abstracts 2011;118(21):2814
   Google Scholar
• Mesa RA, Salama ME, Giles JLK, et al. Phase I study of LY2784544, a JAK2 selective inhibitor, in patients with myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET). Blood 2013;122(21):665
   Google Scholar
• Purandare AV, McDevitt TM, Wan H, et al. Characterization of BMS-911543, a functionally selective small-molecule inhibitor of JAK2. Leukemia 2012;26(2):280-8
   PubMed Web of Science ®Google Scholar
• Roberts AW, Seymour JF, Burbury K, et al. BMS-911543, a selective JAK2 inhibitor: a multicenter phase 1/2a study in myelofibrosis. Blood 2013;122(21):664
   Google Scholar
• Nakaya Y, Shide K, Niwa T, et al. Efficacy of NS-018, a potent and selective JAK2/Src inhibitor, in primary cells and mouse models of myeloproliferative neoplasms. Blood Cancer J 2011;1(7):e29
   PubMed Web of Science ®Google Scholar
• Santos FP, Kantarjian HM, Jain N, et al. Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. Blood 2010;115(6):1131-6
   PubMed Web of Science ®Google Scholar
• Moliterno AR, Hexner E, Roboz GJ, et al. An open-label study of CEP-701 in patients with JAK2 V617F-positive PV and ET: update of 39 enrolled patients. ASH Annual Meeting Abstracts 2009;114(22):753
   Google Scholar
• Paquette R. A phase I study of XL019, a selective JAK2 inhibitor, in patients with polycythemia vera. Blood 2008;112:Abstract 2180
   Google Scholar
• Hedvat M, Huszar D, Herrmann A, et al. The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell 2009;16(6):487-97
   PubMed Web of Science ®Google Scholar
• Tefferi A, Lasho TL, Mesa RA, et al. Lenalidomide therapy in del(5)(q31)-associated myelofibrosis: cytogenetic and JAK2V617F molecular remissions. Leukemia 2007;21(8):1827-8
   PubMed Web of Science ®Google Scholar
• Harrison CN, Heidel FH, Kiladjian J-J, et al. A phase 1b, dose-finding study of ruxolitinib plus panobinostat in patients with primary myelofibrosis (PMF), post–polycythemia vera MF (PPV-MF), or post–essential thrombocythemia MF (PET-MF): identification of the recommended phase 2 dose. Blood 2013;122(21):4045
   Google Scholar
• Keller MD, Rampal RK, Shank K, et al. Improved efficacy of combination of JAK2 and hedgehog inhibitors in myelofibrosis. Blood 2013;122(21):666
   PubMed Web of Science ®Google Scholar
• Alchalby H, Ditschkowski M, Wolf D, et al. Ruxolitinib as pretreatment before allogeneic stem cell transplantation for myelofibrosis. Blood 2013;122(21):392
   Google Scholar
• Koppikar P, Bhagwat N, Kilpivaara O, et al. Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. Nature 2012;489(7414):155-9
   PubMed Web of Science ®Google Scholar
• Deshpande A, Reddy MM, Schade GOM, et al. Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms. Leukemia 2012;26(4):708-15
   PubMed Web of Science ®Google Scholar
• Talpaz M, Gupta V, Savona M, et al. An open-label, phase II study of the JAK1 inhibitor INCB039110 in patients with myelofibrosis. Blood 2013;122(21):663
   Google Scholar
• Begna K, Laborde RR, Patnaik MM, et al. Imetelstat, a telomerase inhibitor, induces morphologic and molecular remissions in myelofibrosis and reversal of bone marrow fibrosis. Blood 2013;122(21):662
   Google Scholar